Summit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual Meeting
28 March 2018 - 10:00PM
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces that it
has been selected for an Emerging Science dual oral and poster
presentation at the 2018 American Academy of Neurology Annual
Meeting taking place 21-27 April 2018 in Los Angeles, CA, US. These
late-breaking presentations will feature the interim 24-week data
from the PhaseOut DMD clinical trial.
Details of the presentations:
Abstract Title: Ezutromid
significantly reduced muscle damage whilst maintaining utrophin in
patients with Duchenne muscular dystrophy (DMD) after 24-weeks of
treatmentAuthors: Francesco Muntoni, Gary Layton,
Indranil Bhattacharya, Crystal Faelan, Anne C Heatherington, David
Roblin, Jon Tinsley, PhaseOut DMD Study Group and Kay E
DaviesSession: Emerging ScienceSession
Date/Time: Tuesday, 24 April 2018, 5:45-7:00pm PDT; Data
Blitz presentation at 6:03pm PDT
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit |
|
|
Glyn Edwards
/ Richard Pye (UK office) |
Tel: |
44 (0)1235 443 951 |
Erik Ostrowski /
Michelle Avery (US office) |
|
+1 617 225 4455 |
|
|
|
Cairn Financial
Advisers LLP (Nominated Adviser) |
Tel: |
+44 (0)20 7213
0880 |
Liam Murray / Tony
Rawlinson |
|
|
|
|
|
N+1
Singer (Joint Broker) |
Tel: |
+44 (0)20 7496
3000 |
Aubrey Powell / Jen
Boorer |
|
|
|
|
|
Panmure
Gordon (Joint Broker) |
Tel: |
+44 (0)20 7886
2500 |
Freddy Crossley,
Corporate Finance |
|
|
Tom Salvesen, Corporate
Broking |
|
|
|
|
|
MacDougall
Biomedical Communications (US) |
Tel: |
+1 781 235 3060 |
Karen Sharma |
|
ksharma@macbiocom.com |
|
|
|
Consilium
Strategic Communications (UK) |
Tel: |
+44 (0)20 3709
5700 |
Mary-Jane Elliott /
Jessica Hodgson / |
|
summit@consilium-comms.com |
Philippa Gardner /
Rosie Phillips |
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024